INSPECS Group plc (AIM:SPEC)
London · Delayed Price · Currency is GBP · Price in GBX 82.00
-1.00 (-1.20%)
May 7, 2026, 2:54 PM GMT
INSPECS Group Market Cap
INSPECS Group has a market cap or net worth of 84.39 million as of May 7, 2026. Its market cap has increased by 107.50% in one year.
Market Cap
84.39M
Enterprise Value
120.36M
Revenue
195.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
82.00
Market Cap Chart
Since February 27, 2020, INSPECS Group's market cap has decreased from 137.95M to 84.39M, a decrease of -38.83%. That is a compound annual growth rate of -7.63%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 6, 2026 | 84.39M | 16.08% |
| Dec 31, 2025 | 72.70M | 57.14% |
| Dec 31, 2024 | 46.26M | -45.83% |
| Dec 29, 2023 | 85.40M | 95.35% |
| Dec 30, 2022 | 43.72M | -88.33% |
| Dec 31, 2021 | 374.78M | 12.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Feb 27, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 209.57B |
| GSK plc | 75.89B |
| Haleon | 30.56B |
| Smith & Nephew | 9.80B |
| Bioventix | 90.13M |
| Shield Therapeutics | 84.41M |
| Faron Pharmaceuticals Oy | 82.80M |
| 4basebio | 78.16M |